Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Vaccines"" wg kryterium: Temat


Tytuł:
Shigella Vaccines: The Continuing Unmet Challenge.
Autorzy:
Lu T; Department of Veterinary Pathobiology and Bond Life Science Center, University of Missouri, Columbia, MO 65201, USA.
Das S; Department of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD 21201, USA.
Howlader DR; Department of Veterinary Pathobiology and Bond Life Science Center, University of Missouri, Columbia, MO 65201, USA.
Picking WD; Department of Veterinary Pathobiology and Bond Life Science Center, University of Missouri, Columbia, MO 65201, USA.
Picking WL; Department of Veterinary Pathobiology and Bond Life Science Center, University of Missouri, Columbia, MO 65201, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Apr 13; Vol. 25 (8). Date of Electronic Publication: 2024 Apr 13.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Shigella Vaccines*/immunology
Shigella Vaccines*/administration & dosage
Dysentery, Bacillary*/prevention & control
Dysentery, Bacillary*/immunology
Shigella*/immunology
Shigella*/pathogenicity
Humans ; Animals ; Vaccines, Subunit/immunology ; Vaccine Development ; Vaccines, Attenuated/immunology
Czasopismo naukowe
Tytuł:
A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.
Autorzy:
Iwata S; Department of Infectious Diseases, National Cancer Center Hospital, Tokyo, Japan.
Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.; the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Tada Y; Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
Omoto S; Biopharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan.
Shibata RY; Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
Igarashi K; Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
Hasegawa T; Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
Ariyasu M; Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan. .
Sonoyama T; Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Apr 29; Vol. 14 (1), pp. 9830. Date of Electronic Publication: 2024 Apr 29.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; Multicenter Study
MeSH Terms:
Antibodies, Neutralizing*/immunology
Antibodies, Neutralizing*/blood
Antibodies, Viral*/blood
Antibodies, Viral*/immunology
COVID-19*/prevention & control
COVID-19*/immunology
COVID-19*/virology
COVID-19 Vaccines*/immunology
COVID-19 Vaccines*/administration & dosage
Spike Glycoprotein, Coronavirus*/immunology
Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; ChAdOx1 nCoV-19 ; East Asian People ; Immunoglobulin G/blood ; Immunoglobulin G/immunology ; Japan ; Vaccines, Subunit/administration & dosage ; Vaccines, Subunit/immunology ; Vaccines, Synthetic/immunology ; Vaccines, Synthetic/administration & dosage
Czasopismo naukowe
Tytuł:
Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response.
Autorzy:
Qi H; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China. .; Newish Biological R&D Center, Wuxi, China. .
Sun Z; State Key Laboratory of Elemento-Organic Chemistry, College of Chemistry, Nankai University, Tianjin, 300071, China.; Newish Biological R&D Center, Wuxi, China.
Gao T; Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Yao Y; Newish Biological R&D Center, Wuxi, China.
Wang Y; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China.; Newish Biological R&D Center, Wuxi, China.
Li W; Newish Biological R&D Center, Wuxi, China.
Wang X; Newish Biological R&D Center, Wuxi, China.
Wang X; Newish Biological R&D Center, Wuxi, China.
Liu D; Newish Biological R&D Center, Wuxi, China.
Jiang JD; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China. .
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2024 Mar 08; Vol. 23 (1), pp. 46. Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Vaccines, DNA*/genetics
Papillomavirus Vaccines*/genetics
Neoplasms*/genetics
Neoplasms*/therapy
Oncogene Proteins, Viral*/genetics
Cancer Vaccines*
Animals ; Mice ; Nucleic Acid-Based Vaccines ; CD8-Positive T-Lymphocytes ; Papillomavirus E7 Proteins/genetics ; Mice, Inbred C57BL ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial.
Autorzy:
Huang T; Hunan Provincial Center for Disease Control and Prevention, Changsha, 410005, China.
Hu Q; Anhui Zhifei Longcom Biopharmaceutical, Hefei, 230601, China.
Zhou X; Anhui Zhifei Longcom Biopharmaceutical, Hefei, 230601, China.
Yang H; Anhui Zhifei Longcom Biopharmaceutical, Hefei, 230601, China.
Xia W; Hunan Provincial Center for Disease Control and Prevention, Changsha, 410005, China.
Cao F; Xiangtan Center for Disease Control and Prevention, Xiangtan, 411100, China.
Deng M; Anhui Zhifei Longcom Biopharmaceutical, Hefei, 230601, China.
Teng X; Anhui Zhifei Longcom Biopharmaceutical, Hefei, 230601, China.
Ding F; Anhui Zhifei Longcom Biopharmaceutical, Hefei, 230601, China.
Zhong Z; Anhui Zhifei Longcom Biopharmaceutical, Hefei, 230601, China.
Gao L; Hunan Provincial Center for Disease Control and Prevention, Changsha, 410005, China. .
Sun J; Guangdong Provincial Institute of Public Health, Guangzhou, 511430, China. .
Gong L; Anhui Zhifei Longcom Biopharmaceutical, Hefei, 230601, China. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2024 Apr 19; Vol. 24 (1), pp. 413. Date of Electronic Publication: 2024 Apr 19.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
COVID-19*/prevention & control
COVID-19 Vaccines*/adverse effects
Vaccines, Subunit*
Adolescent ; Child ; Humans ; Antibodies, Neutralizing ; Antibodies, Viral ; Immunogenicity, Vaccine ; SARS-CoV-2 ; Vaccines, Inactivated/adverse effects ; Child, Preschool
Czasopismo naukowe
Tytuł:
Expression of the SARS-CoV-2 receptor-binding domain by live attenuated influenza vaccine virus as a strategy for designing a bivalent vaccine against COVID-19 and influenza.
Autorzy:
Stepanova E; Institute of Experimental Medicine, Saint Petersburg, 197022, Russia. .
Isakova-Sivak I; Institute of Experimental Medicine, Saint Petersburg, 197022, Russia.
Mezhenskaya D; Institute of Experimental Medicine, Saint Petersburg, 197022, Russia.
Niskanen S; Joint-Stock Company «BIOCAD» (JSC «BIOCAD») Saint Petersburg, Intracity Municipality the Settlement of Strelna, the Settlement of Strelna, ul. Svyazi, d. 38, str. 1, pomeshch. 89, Saint Petersburg, 198515, Russia.
Matyushenko V; Institute of Experimental Medicine, Saint Petersburg, 197022, Russia.
Bazhenova E; Institute of Experimental Medicine, Saint Petersburg, 197022, Russia.
Rak A; Institute of Experimental Medicine, Saint Petersburg, 197022, Russia.
Wong PF; Institute of Experimental Medicine, Saint Petersburg, 197022, Russia.
Prokopenko P; Institute of Experimental Medicine, Saint Petersburg, 197022, Russia.
Kotomina T; Institute of Experimental Medicine, Saint Petersburg, 197022, Russia.
Krutikova E; Institute of Experimental Medicine, Saint Petersburg, 197022, Russia.
Legotskiy S; Joint-Stock Company «BIOCAD» (JSC «BIOCAD») Saint Petersburg, Intracity Municipality the Settlement of Strelna, the Settlement of Strelna, ul. Svyazi, d. 38, str. 1, pomeshch. 89, Saint Petersburg, 198515, Russia.
Neterebskii B; Joint-Stock Company «BIOCAD» (JSC «BIOCAD») Saint Petersburg, Intracity Municipality the Settlement of Strelna, the Settlement of Strelna, ul. Svyazi, d. 38, str. 1, pomeshch. 89, Saint Petersburg, 198515, Russia.
Ostroukhova T; Joint-Stock Company «BIOCAD» (JSC «BIOCAD») Saint Petersburg, Intracity Municipality the Settlement of Strelna, the Settlement of Strelna, ul. Svyazi, d. 38, str. 1, pomeshch. 89, Saint Petersburg, 198515, Russia.
Sivak K; Smorodintsev Research Institute of Influenza, Saint Petersburg, 197376, Russia.
Orshanskaya Y; Smorodintsev Research Institute of Influenza, Saint Petersburg, 197376, Russia.
Yakovlev K; Smorodintsev Research Institute of Influenza, Saint Petersburg, 197376, Russia.
Rudenko L; Institute of Experimental Medicine, Saint Petersburg, 197022, Russia.
Pokaż więcej
Źródło:
Virology journal [Virol J] 2024 Apr 09; Vol. 21 (1), pp. 82. Date of Electronic Publication: 2024 Apr 09.
Typ publikacji:
Journal Article
MeSH Terms:
Influenza, Human*
Influenza Vaccines*/genetics
COVID-19*
Spike Glycoprotein, Coronavirus*
Humans ; Animals ; Mice ; SARS-CoV-2/genetics ; COVID-19 Vaccines ; Vaccines, Combined ; Antibodies, Viral ; Hemagglutinins
Czasopismo naukowe
Tytuł:
Planting a chemical flag on antigens.
Autorzy:
Kunjapur AM; Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2024 Apr 05; Vol. 384 (6691), pp. 41-42. Date of Electronic Publication: 2024 Apr 04.
Typ publikacji:
Journal Article
MeSH Terms:
Amino Acids*/chemistry
Amino Acids*/immunology
Antigens*/chemistry
Antigens*/immunology
Bacterial Vaccines*/chemistry
Bacterial Vaccines*/immunology
Nitrates*/chemistry
Nitrates*/immunology
Bacteria/immunology ; Immunogenicity, Vaccine ; Vaccines, Live, Unattenuated/chemistry ; Vaccines, Live, Unattenuated/immunology
Czasopismo naukowe
Tytuł:
A Bacterium-like Particle Vaccine Displaying Envelope Proteins of Canine Distemper Virus Can Induce Immune Responses in Mice and Dogs.
Autorzy:
Liu L; College of Veterinary Medicine, Jilin University, Changchun 130000, China.; Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Wang J; College of Veterinary Medicine, Jilin Agricultural University, Changchun 130122, China.
Li R; Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.; College of Veterinary Medicine, Jilin Agricultural University, Changchun 130122, China.
Wu J; Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.; College of Veterinary Medicine, Jilin Agricultural University, Changchun 130122, China.
Zhao Y; Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Yan F; Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Wang T; Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Gao Y; Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Zhao Z; Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Feng N; Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.; College of Veterinary Medicine, Jilin Agricultural University, Changchun 130122, China.
Xia X; Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.; College of Veterinary Medicine, Jilin Agricultural University, Changchun 130122, China.
Pokaż więcej
Źródło:
Viruses [Viruses] 2024 Mar 31; Vol. 16 (4). Date of Electronic Publication: 2024 Mar 31.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Distemper Virus, Canine*/immunology
Distemper*/prevention & control
Distemper*/immunology
Antibodies, Neutralizing*/blood
Antibodies, Neutralizing*/immunology
Antibodies, Viral*/blood
Antibodies, Viral*/immunology
Viral Vaccines*/immunology
Viral Vaccines*/administration & dosage
Animals ; Dogs ; Mice ; Female ; Immunoglobulin G/blood ; Vaccines, Virus-Like Particle/immunology ; Vaccines, Virus-Like Particle/administration & dosage ; Viral Envelope Proteins/immunology ; Viral Envelope Proteins/genetics ; Mice, Inbred BALB C ; Cytokines/metabolism ; Vaccination
Czasopismo naukowe
Tytuł:
In silico designed novel multi-epitope mRNA vaccines against Brucella by targeting extracellular protein BtuB and LptD.
Autorzy:
Shi J; Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, No. 393, Xinyi Road, Urumqi, 830011, Xinjiang, China.
Zhu Y; Department of Reproductive Assistance, Center forReproductive Medicine, The First Affiliated Hospital of Xinjiang Medical University, No. 393, Xinyi Road, Urumqi, 830011, Xinjiang, China.
Yin Z; Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, No. 393, Xinyi Road, Urumqi, 830011, Xinjiang, China.
He Y; Department of Immunology, School of Basic Medical Sciences, Xinjiang Medical University, No. 393, Xinyi Road, Urumqi, 830011, Xinjiang, China.
Li Y; Department of Blood Transfusion, First Affiliated Hospital of Xinjiang Medical University, No. 393, Xinyi Road, Urumqi, 830011, Xinjiang, China.
Haimiti G; Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, No. 393, Xinyi Road, Urumqi, 830011, Xinjiang, China.
Xie X; Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, No. 393, Xinyi Road, Urumqi, 830011, Xinjiang, China.
Niu C; Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, No. 393, Xinyi Road, Urumqi, 830011, Xinjiang, China.
Guo W; Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, No. 393, Xinyi Road, Urumqi, 830011, Xinjiang, China.
Zhang F; State Key Laboratory of Pathogenesis, Prevention, Treatment of Central Asian High Incidence Diseases, the First Affiliated Hospital of Xinjiang Medical University, No. 393, Xinyi Road, Urumqi, 830011, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 27; Vol. 14 (1), pp. 7278. Date of Electronic Publication: 2024 Mar 27.
Typ publikacji:
Journal Article
MeSH Terms:
Brucella*/genetics
Vaccines*
Escherichia coli Proteins*
Humans ; mRNA Vaccines ; Escherichia coli ; Lipopolysaccharides ; Epitopes, T-Lymphocyte ; Epitopes, B-Lymphocyte ; T-Lymphocytes, Cytotoxic ; Molecular Dynamics Simulation ; Vaccines, Subunit ; Computational Biology ; Molecular Docking Simulation ; Bacterial Outer Membrane Proteins/genetics
Czasopismo naukowe
Tytuł:
A Cocktail of Lipid Nanoparticle-mRNA Vaccines Broaden Immune Responses against β-Coronaviruses in a Murine Model.
Autorzy:
Zhang Y; Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.; Shanghai Biological Products Research Institute Co., Ltd., State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, Shanghai 200052, China.
Zhang J; Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China.
Li D; Shanghai Biological Products Research Institute Co., Ltd., State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, Shanghai 200052, China.
Mao Q; Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
Li X; Shanghai Biological Products Research Institute Co., Ltd., State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, Shanghai 200052, China.
Liang Z; Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
He Q; Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
Pokaż więcej
Źródło:
Viruses [Viruses] 2024 Mar 21; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 21.
Typ publikacji:
Journal Article
MeSH Terms:
Viral Vaccines*/genetics
Severe acute respiratory syndrome-related coronavirus*/genetics
Liposomes*
Nanoparticles*
Animals ; Mice ; Humans ; mRNA Vaccines ; SARS-CoV-2/genetics ; COVID-19 Vaccines ; Spike Glycoprotein, Coronavirus/genetics ; Disease Models, Animal ; Antibodies, Neutralizing ; RNA, Messenger/genetics ; Immunity ; Antibodies, Viral
Czasopismo naukowe
Tytuł:
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
Autorzy:
Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Andersen-Nissen E; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa.
Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Dintwe OB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa.
Omar FL; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa.
Kee JJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Bekker LG; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Laher F; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Naicker N; Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa; and Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.
Jani I; Instituto Nacional de Saude, Maputo, Mozambique.
Mgodi NM; Clinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Hunidzarira P; Clinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Sebe M; Aurum Institute, Tembisa, Gauteng, South Africa.
Miner MD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Polakowski L; DAIDS, NIAID, NIH, Bethesda, Maryland, United States of America.
Ramirez S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Nebergall M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Takuva S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Sikhosana L; Hutchinson Centre Research Institute of South Africa, Johannesburg, South Africa.
Heptinstall J; Department of Surgery, Duke University, Durham, North Carolina, United States of America.
Seaton KE; Department of Surgery, Duke University, Durham, North Carolina, United States of America.
De Rosa S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Diazgranados CA; Formerly Sanofi-Pasteur, Swiftwater, Pennsylvania, Pennsylvania, United States of America.
Koutsoukos M; GSK, Wavre, Belgium.
Van Der Meeren O; Previously GSK, Rixensart, Belgium.
Barnett SW; Bill & Melinda Gates Foundation, Seattle, Washington, United States of America.
Kanesa-Thasan N; Formerly GSK, Rockville, Maryland, United States of America.
Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Tomaras GD; Department of Surgery, Duke University, Durham, North Carolina, United States of America.
McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Mngadi K; Aurum Institute, Tembisa, Gauteng, South Africa.
Goepfert P; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Pokaż więcej
Corporate Authors:
HVTN 107 Protocol Team
Źródło:
PLoS medicine [PLoS Med] 2024 Mar 19; Vol. 21 (3), pp. e1004360. Date of Electronic Publication: 2024 Mar 19 (Print Publication: 2024).
Typ publikacji:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms:
AIDS Vaccines*/adverse effects
Alum Compounds*
HIV Infections*/prevention & control
HIV-1*
Polysorbates*
Squalene*
Adult ; Humans ; Adjuvants, Immunologic ; HIV Antibodies ; Immunogenicity, Vaccine ; Immunoglobulin A ; Immunoglobulin G ; Vaccines, Combined ; Vaccines, Synthetic
Czasopismo naukowe
Tytuł:
Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses.
Autorzy:
Pushko P; Medigen, Inc., 8420 Gas House Pike Suite S, Frederick, MD 21701, USA.
Lukashevich IS; Department of Pharmacology and Toxicology, School of Medicine, Center for Predictive Medicine and Emerging Infectious Diseases, University of Louisville, 505 S Hancock St., Louisville, KY 40202, USA.
Johnson DM; Department of Biotechnology & Bioengineering, Sandia National Laboratories, Livermore, CA 945501, USA.
Tretyakova I; Medigen, Inc., 8420 Gas House Pike Suite S, Frederick, MD 21701, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2024 Mar 10; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 10.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Vaccines, DNA*
Flavivirus*/genetics
Viral Vaccines*
Animals ; Antibodies, Viral ; Vaccines, Attenuated ; DNA ; Mammals
Czasopismo naukowe
Tytuł:
Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection.
Autorzy:
Clever S; Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Limpinsel L; Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
Meyer Zu Natrup C; Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Schünemann LM; Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Beythien G; Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Rosiak M; Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Hülskötter K; Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Gregor KM; Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Tuchel T; Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Kalodimou G; Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
Freudenstein A; Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
Kumar S; Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
Baumgärtner W; Department of Pathology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Sutter G; Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
Tscherne A; Division of Virology, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleißheim, Germany.
Volz A; Institute of Virology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hanover, Germany.
Pokaż więcej
Źródło:
Viruses [Viruses] 2024 Mar 08; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:
Journal Article
MeSH Terms:
SARS-CoV-2*/genetics
COVID-19*/prevention & control
gamma-Globulins*
Melphalan*
Viral Vaccines*
Vaccines, DNA*
Animals ; Humans ; Mice ; COVID-19 Vaccines ; Antibodies, Viral ; Spike Glycoprotein, Coronavirus/genetics ; Vaccination ; Antibodies, Neutralizing
Czasopismo naukowe
Tytuł:
The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality.
Autorzy:
Lobaina Y; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; R&D Department, Yongzhou Zhong Gu Biotechnology Co., Ltd., Yangjiaqiao Street, Lengshuitan District, Yongzhou 425000, China.
Chen R; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China.
Suzarte E; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Ai P; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China.
Huerta V; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Musacchio A; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Silva R; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; BCF: R&D Section, Representative Office BCF in China, Jingtai Tower, No. 24 Jianguomen Wai Street, Chaoyang District, Beijing 100022, China.
Tan C; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China.
Martín A; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Lazo L; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Guillén-Nieto G; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Yang K; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China.
Perera Y; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; R&D Department, Yongzhou Zhong Gu Biotechnology Co., Ltd., Yangjiaqiao Street, Lengshuitan District, Yongzhou 425000, China.; CIGB: Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Hermida L; Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou 425000, China.; Yongzhou Development and Construction Investment Co., Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou 425000, China.; BCF: R&D Section, Representative Office BCF in China, Jingtai Tower, No. 24 Jianguomen Wai Street, Chaoyang District, Beijing 100022, China.
Pokaż więcej
Źródło:
Viruses [Viruses] 2024 Mar 08; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:
Journal Article
MeSH Terms:
COVID-19*/prevention & control
Vaccines*
Animals ; Mice ; Humans ; Administration, Intranasal ; Nucleocapsid Proteins ; Vaccines, Combined ; SARS-CoV-2/genetics ; COVID-19 Vaccines ; Immunity, Mucosal ; Adjuvants, Immunologic ; Antibodies, Viral ; Antibodies, Neutralizing
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
Development of novel Streptococcus equi vaccines with an assessment of their immunizing potentials and protective efficacies.
Autorzy:
Soliman R; Department of Microbiology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
Yousef M; Department of Veterinary Hygiene, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
Gelil SA; Department of Microbiology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
Aboul-Ella H; Department of Microbiology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt. .
Pokaż więcej
Źródło:
BMC veterinary research [BMC Vet Res] 2024 May 03; Vol. 20 (1), pp. 173. Date of Electronic Publication: 2024 May 03.
Typ publikacji:
Journal Article
MeSH Terms:
Streptococcus equi*/immunology
Mice, Inbred BALB C*
Streptococcal Infections*/veterinary
Streptococcal Infections*/prevention & control
Streptococcal Infections*/microbiology
Streptococcal Infections*/immunology
Horse Diseases*/prevention & control
Horse Diseases*/microbiology
Horse Diseases*/immunology
Streptococcal Vaccines*/immunology
Streptococcal Vaccines*/administration & dosage
Streptococcus*
Animals ; Horses ; Rabbits ; Mice ; Female ; Antibodies, Bacterial/blood ; Adjuvants, Immunologic/administration & dosage ; Vaccines, Inactivated/immunology
SCR Organism:
Streptococcus equi subsp. equi
Czasopismo naukowe
Tytuł:
Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.
Autorzy:
Sotirov S; Drug Design and Bioinformatics Lab, Faculty of Pharmacy, Medical University of Sofia, 2, Dunav Str., 1000 Sofia, Bulgaria.
Dimitrov I; Drug Design and Bioinformatics Lab, Faculty of Pharmacy, Medical University of Sofia, 2, Dunav Str., 1000 Sofia, Bulgaria.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Apr 30; Vol. 25 (9). Date of Electronic Publication: 2024 Apr 30.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Cancer Vaccines*/immunology
Cancer Vaccines*/therapeutic use
Antigens, Neoplasm*/immunology
Neoplasms*/immunology
Neoplasms*/therapy
Neoplasms*/prevention & control
Peptides*/immunology
Peptides*/chemistry
Humans ; Vaccines, Subunit/immunology ; Animals ; Clinical Trials as Topic
Czasopismo naukowe
Tytuł:
Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1.
Autorzy:
Sohail MS; Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China.
Ahmed SF; Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia.; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Quadeer AA; Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia.
McKay MR; Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia.; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Pokaż więcej
Źródło:
Viruses [Viruses] 2024 Mar 20; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 20.
Typ publikacji:
Journal Article
MeSH Terms:
COVID-19*/prevention & control
Vaccines*
Humans ; COVID-19 Vaccines ; Epitopes, T-Lymphocyte/genetics ; SARS-CoV-2/genetics ; Spike Glycoprotein, Coronavirus/genetics ; T-Lymphocytes ; Antibodies, Neutralizing ; Antibodies, Viral
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
Perinatal outcomes and sinopharm BBIBP-CorV vaccination during pregnancy.
Autorzy:
Hatami D; Preventive Medicine and Public Health Research Center, Psychosocial Health Research Institute, Department of Community and Family Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Habibelahi A; Neonatal Health Office, Ministry of Health and Medical Education, Tehran, Iran.
Changizi N; Maternal Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Heidarzadeh M; Department of Neonatology, Zahedan University of Medical Sciences, Zahedan, Iran.
Nojomi M; Preventive Medicine and Public Health Research Center, Psychosocial Health Research Institute, Department of Community and Family Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Rast M; Preventive Medicine and Public Health Research Center, Psychosocial Health Research Institute, Department of Community and Family Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Ansari K; Preventive Medicine and Public Health Research Center, Psychosocial Health Research Institute, Department of Community and Family Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Tehrani-Banihashemi A; Preventive Medicine and Public Health Research Center, Psychosocial Health Research Institute, Department of Community and Family Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. .
Pokaż więcej
Źródło:
BMC pregnancy and childbirth [BMC Pregnancy Childbirth] 2024 Mar 11; Vol. 24 (1), pp. 190. Date of Electronic Publication: 2024 Mar 11.
Typ publikacji:
Journal Article
MeSH Terms:
Premature Birth*/epidemiology
COVID-19*/epidemiology
COVID-19*/prevention & control
Pregnancy Complications, Infectious*/epidemiology
Pregnancy Complications, Infectious*/prevention & control
Vaccines, Inactivated*
Infant, Newborn ; Pregnancy ; Female ; Humans ; Stillbirth/epidemiology ; Iran/epidemiology ; Retrospective Studies ; Vaccination ; COVID-19 Vaccines/adverse effects ; Pregnancy Outcome
Czasopismo naukowe
Tytuł:
Enhancing vaccination uptake through community engagement: evidence from China.
Autorzy:
Guan H; Center for Experimental Economics in Education, Shaanxi Normal University, Xian, 710119, China.
Zhang L; Center for Experimental Economics in Education, Shaanxi Normal University, Xian, 710119, China.
Chen X; Center for Experimental Economics in Education, Shaanxi Normal University, Xian, 710119, China.
Zhang Y; College of Economics, Xi'an University of Finance and Economics, Xi'an, 710100, Shaanxi, China. .
Ding Y; Center for Experimental Economics in Education, Shaanxi Normal University, Xian, 710119, China.
Liu W; Center for Experimental Economics in Education, Shaanxi Normal University, Xian, 710119, China.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 May 13; Vol. 14 (1), pp. 10845. Date of Electronic Publication: 2024 May 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
COVID-19*/prevention & control
COVID-19*/epidemiology
COVID-19 Vaccines*/administration & dosage
Vaccination*/statistics & numerical data
Community Participation*
Humans ; China ; Female ; Male ; Adult ; Middle Aged ; Adolescent ; Young Adult ; Vaccination Coverage/statistics & numerical data ; Aged ; SARS-CoV-2 ; Influenza Vaccines/administration & dosage ; Influenza, Human/prevention & control ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł:
Development of membrane protein-based vaccine against lumpy skin disease virus (LSDV) using immunoinformatic tools.
Autorzy:
Salauddin M; Department of Microbiology and Public Health, Khulna Agricultural University, Khulna, Bangladesh.
Kayesh MEH; Department of Microbiology and Public Health, Patuakhali Science and Technology University, Barishal, Bangladesh.
Ahammed MS; Department of Chemistry, Bangladesh University of Engineering and Technology, Dhaka, Bangladesh.
Saha S; Department of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Hossain MG; Department of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Pokaż więcej
Źródło:
Veterinary medicine and science [Vet Med Sci] 2024 May; Vol. 10 (3), pp. e1438.
Typ publikacji:
Journal Article
MeSH Terms:
Lumpy skin disease virus*
Vaccines*
Animals ; Cattle ; Membrane Proteins ; Epitopes, T-Lymphocyte ; Immunoinformatics ; Molecular Docking Simulation ; Escherichia coli ; Protein Subunit Vaccines
Czasopismo naukowe
Tytuł:
Evaluation of the immune response of layer chickens to Newcastle disease virus vaccines using the new vaccination regimens.
Autorzy:
Geletu AS; Ethiopian Institute of Agricultural Research, Wolkite Agricultural Research center, Wolkite, Ethiopia.
Robi DT; Ethiopian Institute of Agricultural Research, Tepi Agricultural Research Center, Tepi, Ethiopia.
Pokaż więcej
Źródło:
Veterinary medicine and science [Vet Med Sci] 2024 May; Vol. 10 (3), pp. e1428.
Typ publikacji:
Randomized Controlled Trial, Veterinary; Journal Article
MeSH Terms:
Newcastle disease virus*
Viral Vaccines*
Animals ; Female ; Chickens ; Antibodies, Viral ; Vaccination/veterinary ; Antibody Formation ; Vaccines, Attenuated
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies